| Description | This product is a human monoclonal antibody that reacts with FLT3. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; WB; DB; FuncS |
| Application Notes | The antibody is recommended for detection of FLT3 by FuncS assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | FLT3 |
| Alternative Name | FLT3; fms-related tyrosine kinase 3; FLK2; STK1; CD135; FLK-2; receptor-type tyrosine-protein kinase FLT3; CD135 antigen; FL cytokine receptor; fetal liver kinase 2; fms-like tyrosine kinase 3; stem cell tyrosine kinase 1; growth factor receptor tyrosine |
| Gene ID | 2322 |
| UniProt | P36888 |
| Research Area | Immunology; Signal Pathway |
Figure 1 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in DB
Dot Blot analysis of V3S-0622-YC4469 was performed by coating with human FLT3 protein (His tag).
V3S-0622-YC4469 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 6000)
Figure 1 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in DB
Figure 2 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in WB
Western blot analysis of V3S-0622-YC4469 was performed by loading human FLT3 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4469 and HRP goat anti-Human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.2 μg)
Lane 2: Reduced antigen (0.4 μg)
Lane 3: Reduced antigen (0.8 μg)
Figure 2 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in WB
Figure 3 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in ELISA
ELISA analysis of V3S-0622-YC4469 was performed by coating with human FLT3 protein (His tag). Then blocked with BSA and incubated with V3S-0622-YC4469. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 6000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-Human FLT3 Monoclonal Antibody (V3S-0622-YC4469) in ELISA
